| Literature DB >> 30576309 |
Ashish Nareshkumar Wagh1, Shivakumar Mugudalabetta1, Nimer Ortuno Gutierrez2, Krishnamurthy Padebettu1, Ajay Kumar Pandey1, Bijoy Kumar Pandey3, Mahalakshmy Thulasingam4, Srinath Satyanarayana5, Amol Dongre6.
Abstract
BACKGROUND: India contributes ~60% to the global leprosy burden. The country implements 14-day community-based leprosy case detection campaigns (LCDC) periodically in all high endemic states. Paramedical staff screen the population and medical officers of primary health centres (PHCs) diagnose and treat leprosy cases. Several new cases were detected during the two LCDCs held in September-2016 and February-2018. Following these LCDCs, a validation exercise was conducted in 8 Primary health centres (PHCs) of 4 districts in Bihar State by an independent expert group, to assess the correctness of case diagnosis. Just before the February 2018 LCDC campaign, we conducted an "appreciative inquiry" (AI) involving the health care staff of these 8 PHCs using the 4-D framework (Discovery-Dream-Design-Destiny).Entities:
Mesh:
Year: 2018 PMID: 30576309 PMCID: PMC6322788 DOI: 10.1371/journal.pntd.0007004
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Classification, treatment regimen & treatment outcomes for leprosy as per national leprosy eradication programme in India.
| Characteristic | PB (Pauci Bacillary) | MB (Multi Bacillary) |
|---|---|---|
| Skin lesions | 1–5 lesions with definite loss of sensation | 6 and above with definite loss of sensation |
| Peripheral nerve involvement | No nerve/ only one nerve | More than one nerve |
| Skin smear | Negative at all sites | Positive at any site |
| Drugs and regimen | Rifampicin (once monthly) | Rifampicin (once monthly) |
| Dapsone (daily) | ||
| Criteria for release from treatment (RFT) | Completion of 6 monthly pulses in 9 consecutive months | Completion of 12 monthly pulses in 18 consecutive months |
Characteristics of the patients diagnosed during Leprosy case detection campaign (LCDC) and cases validated by DFIT in 8 blocks of 4 districts in Bihar, India (2016–2018).
| Characteristics | 2016 | 2018 | ||||
|---|---|---|---|---|---|---|
| LCDC cases | Validated cases | Chi-square test P-value | LCDC cases | Validated cases | Chi-square test P-value | |
| 303 | 196 | 118 | 94 | |||
| N (%) | N (%) | N (%) | N (%) | |||
| <6 | 3 (1) | 2 (1) | 0.199 | 2 (2) | 2 (2) | 0.097 |
| 6–14 | 48 (16) | 37 (19) | 13 (11) | 12 (13) | ||
| 15–30 | 115 (38) | 75 (38) | 44 (37) | 30 (32) | ||
| >30 | 137 (45) | 82 (42) | 59 (50) | 50 (53) | ||
| Male | 142 (47) | 86 (44) | 0.158 | 64 (54) | 46 (49) | 0.022 |
| Female | 161 (53) | 110 (56) | 54 (46) | 48 (51) | ||
| Pauci bacillary | 232 (77) | 153 (78) | 0.406 | 76 (64) | 65 (69) | 0.033 |
| Multi bacillary | 71 (23) | 43 (22) | 42 (36) | 29 (31) | ||
| Nalanda | 50 (17) | 38 (20) | <0.001 | 16 (14) | 16 (17) | 0.015 |
| Sitamarhi | 73 (24) | 47 (24) | 41 (35) | 33 (35) | ||
| Araria | 139 (46) | 75 (38) | 51 (43) | 35 (37) | ||
| Gopalganj | 41 (13) | 36 (18) | 10 (7) | 10 (11) | ||
| 1 | 26 (9) | 17 (9) | 0.001 | 6 (5) | 4 (4) | 0.009 |
| 2 | 24 (8) | 21 (11) | 35 (30) | 29 (31) | ||
| 3 | 39 (13) | 26 (13) | 28 (24) | 18 (19) | ||
| 4 | 34 (11) | 21 (11) | 7 (6) | 7 (7) | ||
| 5 | 91 (30) | 45 (23) | 1 (1) | 1 (1) | ||
| 6 | 48 (16) | 30 (15) | 9 (8) | 9 (10) | ||
| 7 | 19 (6) | 17 (8) | 23 (19) | 17 (18) | ||
| 8 | 22 (7) | 19 (9) | 9 (8) | 9 (10) | ||
Results and themes derived from appreciative inquiry prior to leprosy case detection campaign in Bihar, India (November 2017).
Association of appreciative inquiry and patient characteristics with false positive diagnosis of leprosy during Leprosy case detection campaign in Bihar, India (2016–2018).
| Characteristics of Diagnosis | Total number of Patients validated (N = 290) | False Positive diagnosis | Unadjusted | Adjusted | ||||
|---|---|---|---|---|---|---|---|---|
| N | N | (%) | PR | (95%CI) | PR | (95%CI) | P-value | |
| Before (2016) | 196 | 58 | (29.6) | Ref | - | Ref | - | |
| After (2018) | 94 | 22 | (23.4) | 0.89 | (0.72–1.10) | 0.67 | (0.44–1.03) | 0.068 |
| <6 | 4 | 2 | (50.0) | 2.28 | (0.80–6.49) | 1.54 | (0.69–3.44) | 0.291 |
| 6–14 | 49 | 8 | (16.3) | 0.74 | (0.35–1.54) | 0.69 | (0.34–1.39) | 0.306 |
| 15–30 | 105 | 23 | (21.9) | Ref | Ref | |||
| >30 | 132 | 47 | (35.6) | (0.99–2.26) | 0.054 | |||
| Male | 132 | 38 | (28.8) | Ref | Ref | |||
| Female | 158 | 42 | (26.6) | 0.92 | (0.63–1.34) | 1.00 | (0.70–1.45) | 0.960 |
| Pauci Bacillary | 218 | 61 | (28.0) | Ref | Ref | |||
| Multi Bacillary | 72 | 19 | (26.4) | 0.94 | (0.60–1.46) | 0.83 | (0.54–1.26) | 0.395 |
| 1 | 30 | 3 | (10.0) | Ref | Ref | |||
| 2 | 50 | 17 | (34.0) | 3.85 | (1.22–12.10) | |||
| 3 | 63 | 29 | (46.0) | 4.94 | (1.65–14.75) | |||
| 4 | 28 | 5 | (17.9) | 1.78 | (0.46–6.80) | 1.96 | (0.52–7.36) | 0.314 |
| 5 | 18 | 3 | (16.7) | 1.66 | (0.37–7.41) | 2.27 | (0.52–9.89) | 0.272 |
| 6 | 26 | 11 | (42.3) | 5.38 | (1.69–17.09) | |||
| 7 | 47 | 11 | (23.4) | 2.35 | (0.70–7.72) | 2.88 | (0.89–9.34) | 0.077 |
| 8 | 28 | 1 | (3.6) | 0.35 | (0.03–3.22) | 0.43 | (0.48–3.92) | 0.460 |
*PR = Prevalence ratio (of false positive leprosy diagnosis); 95% CI = 95% Confidence intervals